CONFERENCE COVERAGE SERIES
Clinical Trials on Alzheimer’s Disease 2013
San Diego, CA
14 – 16 November 2013
Are New Cognitive Tests Ready For Preclinical Trials?
Meet ADCS-PACC, C3: Composites that measure subtle changes in cognition appear reliable, clearing the way for their use in clinical trials of people with presymptomatic AD.
Do Tau Tracers Track Cognitive Decline in Disease?
In the early days of tau brain imaging, neurofibrillary pathology appears to match up with the subtle cognitive decline of presymptomatic Alzheimer’s.
Growth Factor Therapy: Safe in Phase 1, Awaiting Efficacy Data
A gene therapy approach to protect cholinergic neurons appeared safe and seemed to stabilize brain metabolism in a Phase 1 trial of AD patients.